Collegium Pharmaceutical (COLL) Cash from Operations (2014 - 2026)

Collegium Pharmaceutical has reported Cash from Operations for 13 years, with the latest figure at $71.3 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 1.54% year-over-year to $71.3 million in Q2 2026; TTM through Jun 2026 was $329.9 million, a 62.14% increase from a year earlier, with the FY2025 full-year figure at $329.3 million, up 60.66% from the prior year.
• Cash from Operations was $71.3 million for Q2 2026 at Collegium Pharmaceutical, up from $57.1 million in the prior quarter.
• The five-year high for Cash from Operations was $123.0 million in Q4 2025, with the low at -$25.3 million in Q1 2022.
• Average Cash from Operations over 5 years is $59.0 million, with a median of $66.9 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Cash from Operations sank 223.07% in 2022, then surged 971.63% in 2025.
• Over 5 years, Cash from Operations stood at $66.3 million in 2022, then grew by 10.57% to $73.3 million in 2023, then advanced by 15.42% to $84.6 million in 2024, then surged by 45.37% to $123.0 million in 2025, then plunged by 42.04% to $71.3 million in 2026.
• The last three Cash from Operations figures came in at $71.3 million (Q2 2026), $57.1 million (Q1 2026), and $123.0 million (Q4 2025), per Business Quant data.